Disease Overview：Myelodysplastic Syndromes（MDS）
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, dysplasia in one or more myeloid lineages, and an increased risk of progression to acute myeloid leukemia (AML). Diagnosis relies on integrated assessment of peripheral blood morphology, bone marrow aspirate and biopsy with cytogenetic analysis (e.g., karyotyping, FISH), and molecular profiling (e.g., mutations in *SF3B1*, *TET2*, *ASXL1*, *TP53*). Risk stratification—using systems such as the Revised International Prognostic Scoring System (IPSS-R)—guides therapeutic decisions ranging from supportive care and growth factor administration to hypomethylating agents (azacitidine, decitabine), immunomodulatory drugs, allogeneic hematopoietic stem cell transplantation (allo-HSCT), and emerging targeted therapies.
China offers distinct advantages for MDS management: leading hematology centers—many affiliated with top-tier universities—boast extensive experience in complex MDS subtyping, minimal residual disease monitoring via next-generation sequencing, and high-volume allo-HSCT programs with outcomes comparable to Western benchmarks. Advanced infrastructure includes PET-CT, digital pathology platforms, and centralized biobanks supporting precision oncology trials. Treatment costs in China average 40–60% lower than in the U.S. or Western Europe, without compromising clinical rigor or regulatory compliance (NMPA-approved therapeutics, CAP/ISO-accredited labs).
As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating appointments with certified hematologists, verifying hospital credentials, providing itemized, transparent pricing, arranging visa support, accommodation, and multilingual clinical liaison—ensuring continuity of care from consultation through follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Myelodysplastic Syndromes (MDS)
Non-Surgical / Conservative / Medication-Based Therapy
*Indicated for lower-risk MDS (IPSS-R Low/Intermediate), elderly patients, or those unfit for intensive therapy.*
- •Supportive Care
- Platelet transfusions: $110–$160/unit - Iron chelation (deferasirox, 500 mg/day): $420–$580/month (brand-name; generic ~$190/month) - Erythropoiesis-stimulating agents (epoetin alfa, 40,000 IU SC weekly): $310–$440/month
- •Disease-Modifying Agents
*Eligibility: del(5q) cytogenetic abnormality, transfusion-dependent anemia* - Azacitidine (75 mg/m² IV × 7 days/cycle, q28d): $2,900–$3,600/cycle *Includes drug, infusion nursing, daily CBC/diff, renal/liver panel ($45–$65)* - Decitabine (20 mg/m² IV × 5 days/cycle, q28d): $2,400–$3,100/cycle *Includes drug, infusion, labs ($40–$60), ECG ($25)*
Surgical / Procedural / Interventional Therapy
*Reserved for higher-risk MDS (IPSS-R High/Very High), fit patients <75 years, with HLA-matched donor.*
- •Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
- Conditioning regimen (fludarabine/busulfan or reduced-intensity): $3,400–$5,200 - Stem cell collection & infusion: $8,900–$12,600 - Inpatient hospitalization (30–45 days, including GVHD prophylaxis, antimicrobials, supportive care): $24,500–$36,000 - Total estimated range: $38,900–$56,600
Special / Complex Condition Management
- •Refractory Anemia with Excess Blasts (RAEB-2) progressing to AML: Urgent transition to intensive induction (cytarabine + idarubicin) → $4,700–$6,300/cycle, followed by allo-HSCT if eligible.
- •TP53-mutated MDS: Hypomethylating agent + venetoclax off-label use: $5,100–$6,800/month, plus mandatory MRD monitoring (flow cytometry + NGS, $380–$520/test).
- •Severe neutropenia with recurrent life-threatening infection: Granulocyte colony-stimulating factor (G-CSF, 5 µg/kg SC daily): $180–$260/month.
Quick Selection Guide
- •Age <60, IPSS-R High/Very High, no major comorbidities: Allo-HSCT — only curative option; prioritize early donor search.
- •Age 65–75, Intermediate risk, mild comorbidities: Azacitidine monotherapy — balances efficacy, tolerability, and cost ($3,250 avg/cycle).
- •Age >75, Low-risk, transfusion-dependent: Lenalidomide (if del[5q]) or supportive care + ESA — avoids toxicity; monthly cost <$600.
- •Budget-constrained, any age: Generic azacitidine + transfusion support — reduces annual cost by ~40% vs. brand; requires strict adherence to lab monitoring schedule.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Myelodysplastic Syndromes Medical Vacation Packages
Curated transparent all-inclusive packages combining Myelodysplastic Syndromes treatment with China top medical destinations:
